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Abstract Lipoprotein(a) [Lp(a)] is a highly atherogenic
lipoprotein that is under strong genetic control by the
LPA gene locus. Genetic variants including a highly
polymorphic copy number variation of the so called
kringle IV repeats at this locus have a pronounced in-
fluence on Lp(a) concentrations. High concentrations of
Lp(a) as well as genetic variants which are associated
with high Lp(a) concentrations are both associated with
cardiovascular disease which very strongly supports cau-
sality between Lp(a) concetrations and cardiovascular
disease. This method of using a genetic variant that
has a pronounced influence on a biomarker to support
causality with an outcome is called Mendelian random-
ization approach and was applied for the first time two
decades ago with data from Lp(a) and cardiovascular
disease. This approach was also used to demonstrate a
causal association between high Lp(a) concentrations
and aortic valve stenosis, between low concentrations
and type-2 diabetes mellitus and to exclude a causal
association between Lp(a) concentrations and venous
thrombosis. Considering the high frequency of these ge-
netic variants in the population makes Lp(a) the stron-
gest genetic risk factor for cardiovascular disease iden-
tified so far. Promising drugs that lower Lp(a) are on
the horizon but their efficacy in terms of reducing clin-
ical outcomes still has to be shown.
Keywords lipoprotein(a) . Apolipoprotein(a) .
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Introduction
Lipoprotein(a) [Lp(a)] consists of an LDL particle and
the glycoprotein apolipoprotein(a) [apo(a)] which is
linked to the apolipoprotein B from LDL by a single
disulfide bond [1]. It is synthesized in the liver but the
site and mechanism of catabolism is discussed contro-
versially: no receptor specific for Lp(a)/apo(a) has been
described but several observations point to a role of the
kidney in Lp(a) catabolism [1–3].
An astonishing characteristic of Lp(a) is the more
than 1000-fold range of concentrations between individ-
uals from less than 0.1 mg/dL to more than 300 mg/dL
with a skewed distribution in most populations
(Fig. 1a). Lp(a) concentrations are not very much influ-
enced by age, sex, fasting state, inflammation [4, 5] and
lifestyle factors such as diet or physical activity but are
under strict genetic control by the LPA gene locus and
here especially by a size polymorphism of apo(a)
caused by a variable number of kringle IV (KIV) re-
peats in the LPA gene [1, 6].
The physiological function of Lp(a) is still unclear.
Medical interest in Lp(a) started when it was discovered
that high Lp(a) plasma concentrations are associated
with cardiovascular disease (CVD). The high homology
of apo(a) and plasminogen [7] directed research to the
fibrinolytic system and it was suggested that Lp(a) may
act as a modulator of the balance between blood
clotting and fibrinolysis. Numerous studies mostly done
in vitro found that Lp(a) indeed interferes with the
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blood clotting/fibrinolytic cascades by e.g., inhibition of
streptokinase and urokinase-mediated activation of plas-
minogen by the tissue-type plasminogen activator (t-
PA), inhibition of t-PA in solution, fibrin and fibrinogen
binding, competition with plasminogen and t-PA binding
for soluble fibrinogen, competition with plasminogen for
binding to cellular receptors, and enhancement of the
plasminogen-activator-inhibitor PAI-1 activity (reviewed
in [8]). From the more than 1000-fold interindividual
range in Lp(a) concentrations one would expect major
influences on the involved systems also in vivo but this
has not been described convincingly.
An unexpected and intriguing observation is the binding of
oxidized phospholipids (OxPl) to apo(a) of the Lp(a) particle
[9, 10]. Levels of Lp(a) and OxPl in human plasma are highly
correlated, suggesting that individuals with high Lp(a) have a
higher binding capacity for OxPl and have more OxPl in their
plasma. Lp(a) has therefore been proposed to function as a
Bsink^ for OxPl [11]. Not unexpectedly this association also
results in an association of OxPl levels with CVD [12, 13].
LPA Gene and Structure of Lp(a)
To understand the genetics of Lp(a) one first has to understand
the structure of the LPA gene and how this structure has de-
veloped during evolution. The LPA gene evolved by duplica-
tion and remodeling from the plasminogen (PLG) gene during
primate evolution and is only present in old world monkeys
and primates including humans [7, 14]. This limits research
considerably since most animal models might be restricted
due to the fact that these model organisms might miss besides
the LPA gene also the other genes for the machinery involved
in the synthesis and catabolism of Lp(a).
PLG contains five types of kringle domains called KI to
KV and a protease domain. The human LPA gene does not
have KI to KIII, but KIV, KV and the protease domain are
present. The peculiarity for LPA is the KIV which has expand-
ed and diversified by mutation into ten different types (KIV
type 1–10).Within these ten different types the KIV-2 exists in
multiple copies ranging from two to more than 40 repeats.
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Fig. 1 Panel a, distribution of
Lp(a) concentration in 6218
individuals from the two
population-based studies KORA
F3 and F4. Panel b, median Lp(a)
concentrations in various groups
of subjects stratified by the
number of KIV repeats and
genotypes of SNP rs10455872;
11–22 KIV repeats are considered
as low molecular weight (LMW)
or small apo(a) isoforms and
those with >22 KIV repeats are
considered as high molecular
weight (HMW) or large apo(a)
isoforms. Figure adapted and
reprinted with permission of
reference [107]
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highly polymorphic and informative copy number variation
(CNV) with a heterozygosity of more than 95 % in most
populations.
The KIV-2 CNV is transcribed into mRNA and translated
into the apo(a) isoform protein. During the assembly to the
Lp(a) particle, the apo(a) isoform binds covalently to apolipo-
protein B of an LDL particle in a stoichiometric manner and
forms the Lp(a) particle [15].
The LPA gene is highly expressed in the liver but not in
other organs [7]. The regulation of expression is not very well
understood. Transcription factor binding sites in the 5′-region
of the LPA gene are known for HNF1α, HNF4α, sex hor-
mones and acute phase inducers. A retinoid response element
is present in the LPA promoter and an enhancer residing in a
LINE element has been found in the intragenic region be-
tween LPA and PLG [16]. An Ets binding element in the
human LPA promoter functions as an ELK-1 binding site that
mediates repression of LPA transcription by FGF19 [17].
Interestingly, LPA gene expression is downregulated by bile
acids and the effect is mediated by the farnesoid-X receptor
(FXR), which represses hepatic LPA gene expression in
humans by inferring with HNF4α. It was demonstrated that
the LPA promoter contains a direct repeat element-1 (DR-1)
between nucleotides −826 and −814 to which HNF4α binds
promoting LPA transcription [18]. FXR competes with
HNF4α for binding to the DR-1 element. Modulation of
FXR has therefore been proposed as a potential target for
Lp(a) lowering drugs.
Genetic Variability and Influence on Lp(a)
Concentrations
Figure 2 provides an overview on the most important genetic
and non-genetic factors that have an influence on Lp(a) con-
centrations. Some of them play different roles in various
populations.
KIV Repeat Polymorphism
The interindividual range of Lp(a) concentrations is very wide
from less than 0.1 mg/dL to more than 300 mg/dL. Few peo-
ple lack Lp(a) in their plasma [19, 20]. The broad range in the
Lp(a) distribution is known for all populations and is highly
skewed towards low levels in most ethnic groups. Figure 1a
demonstrates in a population-based study from Southern
Germany that roughly 50 % of the individuals have concen-
trations below 10 mg/dL. Approximately 25 % of this typical
population have concentrations above 30 mg/dL and 14 %
have concentrations above 50 mg/dL. Both thresholds have
been considered to be associated with an increased risk for
cardiovascular disease [1, 21]. In contrast to European and
Asian populations sub-Saharian Africans show markedly
higher Lp(a) concentrations with a distribution that is closer
to a Gaussian distribution.
These substantial differences between individuals are to a
large extent genetically determined. Early family studies
established the genetic nature of the trait and twin studies
found that the heritability of Lp(a) is very high, exceeding
90 % in populations of European and African descent [22,
23]. Lp(a) is therefore the lipoprotein with the strongest ge-
netic control. The discovery of the size polymorphism of
apo(a) in serum [24] and KIV-2 CNV in the LPA gene [6,
25–27] resulted in the identification of the LPA gene as the
major gene for Lp(a) levels. Association and sib-pair linkage
studies [27–31] revealed very soon that the KIV repeat size
polymorphism explains a major part of this variance ranging
from 30 to 70 % depending on the ethnic population [1].
Individuals expressing a low number of K-IV repeats resulting
in so-called small apo(a) isoforms (up to 22 KIV repeats) have
on average markedly higher Lp(a) concentrations than indi-
viduals carrying only large apo(a) isoforms (more than 22
KIV repeats) (Fig. 1b).
Other Genetic Variants Besides the KIV Repeat
Polymorphism
Despite this pronounced inverse correlation between the
number of KIV repeats and the Lp(a) concentrations,
there is still a wide variability in Lp(a) concentrations
within each KIV repeat group. That means isoforms of
the same size differ widely in concentrations. This sug-
gests that besides non-genetic factors other genetic var-
iants than the KIV repeats are major contributors to
Lp(a) concentration variation and that there are pro-
nounced differences between ethnicities. And indeed
several dozens of genetic variants within the LPA gene
region have been described in the meanwhile and for
most of them, the functional consequences are not yet
known. This has to be seen in the context that a genetic
variant can be in strong linkage disequilibrium with the
real causal variant and without functional studies it will
be hard to determine which variant is functionally re-
sponsible for Lp(a) concentration variability. One of the
first additional polymorphisms besides the KIV repeat
polymorphism described to be associated with Lp(a)
concentrations was a pentanucleotide repeat polymor-
phism in the promoter region of the LPA gene [32,
33]. This polymorphism explains up to 14 % of the
Lp(a) variation in Europeans but shows no association
in Black Africans [32]. However, functional promoter
studies suggested that causal variants in linkage disequi-
librium with the pentanucleotide repeat polymorphism
rather than pentanucleotide repeat polymorphism itself
are contributing to Lp(a) concentrations [34, 35].
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There are two SNPs known which are functionally charac-
terized and which result in non-expressed apo(a) alleles. A +1
donor splice site mutation (rs41272114) with a frequency of
about 6 % in Europeans results in alternate splicing leading to
a truncated apo(a) isoform with congenital deficiency of Lp(a)
[19, 36]. Another SNP in the first exon of KIV type-2 intro-
duces a stop codon resulting in a truncated apo(a) protein. This
nonsense mutation causing a null allele is observed in a fre-
quency of 2 % in Europeans [20].
Besides these well characterized variants several dozens of
SNPs in the wider LPA region have recently been brought to
the attention of the scientific community [37]. Many of them
show pronounced associations with Lp(a) concentrations
(e.g., rs10455872 and rs3798220) but the functional signifi-
cance is not yet clear. Furthermore, since sequencing of the
highly repetitive and large KIV type-2 repeat is until now hard
to accomplish, we might expect some surprises on genetic
variants in those regions which could have a pronounced ef-
fect on Lp(a) concentrations.
Genome-Wide Association Studies (GWAS)
The search for Lp(a)-modifying genes using genome-wide
association studies (GWAS) is in progress. GWAS performed
up to now were strongly limited by sample size, focus on
certain subgroups (e.g., diabetes mellitus, population isolates)
or by the use of a specialized candidate gene-chip. Due to
these limitations they were only able to identify the well-
known region on chromosome 6q27 harboring LPA, PLG,
SLC22A3 [38–42] and very recently the APOE gene locus in
African Americans [43]. This finding will require confirma-
tion in different populations and functional elucidation. It will
require a large number of samples to identify further genes
contributing to Lp(a) levels, should such loci exist. A condi-
tional analysis adjusted for the effects of the LPA locus and
especially the apo(a) isoform size will tremendously increase
the power of such GWAS.
Familial Hypercholesterolemia
Two- to three-fold elevated Lp(a) levels were observed in
patients with familial hypercholesterolemia vs. controls in
the majority of larger and well controlled studies that were
matched for apo(a) isoform size. These and other observations
suggested that not only LDL but also Lp(a) may be catabo-
lized by the LDLR pathway. A large sib-pair study [44] and a
study of South African families with familial hypercholester-
olemia [45] included molecularly defined homozygous and
heterozygous patients, in which KIV-2 repeat genotypes and
apo(a) isoforms were determined by Westernblots. They ob-
served a clear dose effect of defective LDLR alleles on Lp(a)
levels: when they binned apo(a) alleles by size they found in
each isoform group Lp(a) levels to increase with the number
of LDL receptor mutations demonstrating a positive gene dos-
age effect.
The mechanism behind the elevated Lp(a) in familial hy-
percholesterolemia is not clear. In vitro cell culture studies and
in vivo turnover studies [46] excluded the LDLR pathway as a
main route of Lp(a) catabolism. This is also in line with the
observation that statins that result in an overexpression of
LDL receptors do not lower Lp(a) concentrations, despite a
pronounced effect on LDL-cholesterol (LDL-C) concentra-
tions [47–49]. Therefore, it is actually not clear which gene
really influences Lp(a) concentrations in the case of familial
hypercholesterolemia.
Why did Genetic Studies Become the Lifeline
for Lp(a) as a Risk Factor for Cardiovascular
Disease?
Association of Lp(a) Concentrations with CVD
There was a major discussion in the mid-1990s whether Lp(a)
is indeed a risk factor for CVD. In the meantime there is very
strong evidence that increasing Lp(a) concentrations are
Lp(a) concentrations
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Fig. 2 Overview on the most
important genetic and non-genetic
factors that have an influence on
Lp(a) concentrations. The
graphical illustration of the Lp(a)
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associated with an increasing risk for CVD. Numerous studies
have been published over the last three decades. Not all were
positive and this resulted in major speculations on the reasons
why some were negative. These speculations included the
selection of appropriate controls, selection of patients, non-
standardization of assays [50, 51] and sample storage effects
[52], to mention only a few. One of the largest studies up to
now, the Copenhagen City Heart Study, observed a 1.6-fold
increased risk for an incident myocardial infarction for con-
centrations between 30 and 76 mg/dL (67th – 90th percentile)
compared to individuals with Lp(a) concentrations below
5 mg/dL (<22nd percentile). This risk increased to 1.90 for
individuals with Lp(a) concentrations between 77 and
117 mg/dL (90th - 95th percentile) and to 2.60 for individuals
with Lp(a) concentrations above 117 mg/dL (>95th percen-
tile) [53] (Fig. 3, panel a).
Mendelian Randomization Studies Using the KIV Repeat
Polymorphism as a New Starting Point
This pronounced association, however, is at first glance not
proof that Lp(a) is causally related to CVD even if the results
come from several prospective studies. As already mentioned,
a major discussion dominated the field in the 1990s since
reverse causation could not be convincingly excluded.
Reverse causation means that elevated Lp(a) in patients with
CVD might be the consequence rather than the cause of the
disease. Only genetic studies following the principle of the
Mendelian randomization approach finally excluded reverse
causation as a reason for elevated Lp(a) in CVD. This ap-
proach became quite popular during the last two decades
and was applied for the first time ever with Lp(a). It is based
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Fig. 3 Mendelian Randomization approach to demonstrate a causal
association between Lp(a) concentrations and coronary heart disease
(CHD). Panel a shows the association between elevated Lp(a)
concentrations and cardiovascular disease (CVD) as shown in the
Copenhagen City Heart Study [53]. Panel b shows the association
between the number of K-IV repeats in the LPA gene and Lp(a)
concentrations: individuals with small apo(a) isoform have markedly
higher median Lp(a) concentrations than individuals with large apo(a)
isoforms. Data are derived from [107]. Panel c shows the
preponderance of small apo(a) isoforms in patients with CVD when
compared to controls. Data are taken from a case–control study in
multiple populations [56]. Since a low number of KIV copies (11–22
copies) is associated with high Lp(a) levels and high Lp(a) levels are
associated with CHD, it follows that a low number of KIV copies has
to be associated with CVD if the association of Lp(a) with CVD is causal
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leg starts with the finding that a biomarker (in our case high
Lp(a) concentrations) is associatedwith CVD (Fig. 3, panel a).
This association could be either causal or the result of reverse
causation in the sense that the outcome CVD is changing the
biomarker secondarily. Furthermore, the association can be
influenced by several confounders. The second leg of the tri-
angle is that certain alleles of genes (in our case this was the
number of KIV repeats determining apo(a) isoform size) have
an influence on Lp(a) concentrations (Fig. 3, panel b).
Figure 4 is a simplified illustration how this random assort-
ment of alleles from parents to offsprings works. If one of the
parents carries one small apo(a) isoform (usually associated
with high Lp(a) concentrations) and one large apo(a) isoform
(associated with low concentrations), it is randomly deter-
mined at the time of conception which of the two alleles will
be transmitted to the offspring. This holds also true for the
alleles of the other parents. It will thereby be determined in
this early stage whether someone is exposed all their life to
lower or higher Lp(a) concentrations. If Lp(a) concentrations
indeed influence the risk for CVD, the triangle will be final-
ized by the third leg (Fig. 3, panel c) as one would expect to
see a preponderance of small apo(a) isoforms in persons who
develop CVD. And this was indeed the case when the first
studies were published in patients with familial hypercholes-
terolemia with and without CHD [54] and Chinese CHD pa-
tients and controls [55] and by a multicenter-multiethnic study
including >1000 CHD cases [56]. In the latter study the OR in
the pooled sample was 1.78 for small apo(a) isoforms. These
were actually the first studies applying theMendelian random-
ization approach in practice, although they did not use this
term which was only introduced in 2003 [57]. Several
follow-up studies, including one in which KIV-2 repeats were
determined by pulsed-field gel electrophoresis [58] and a
meta-analysis of these studies confirmed the association
[59]. The meta-analysis included 40 studies with 11396 cases
and 46938 controls and 30 studies with 7382 cases and 8514
controls that applied broadly comparable phenotyping and
analytic methods. Smaller apo(a) isoforms were associated
with a twofold increased risk for CHD compared to large
isoforms (RR=2.08, 95%CI 1.76-2.58) [59]. Similar relative
risks were observed for ischemic stroke (RR=2.14; 95 % CI:
1.85-2.97) [59]. These pronounced effect sizes are probably
the strongest which will ever be identified for common vari-
ants and CVD, keeping in mind that approximately 25–35 %
of the population carries small apo(a) isoforms (Fig. 3). This
high prevalence of small apo(a) isoforms points to a high
public health relevance.
Mendelian Randomization Studies Using SNPs
The finding of the pronounced association between the num-
ber of KIV repeats and CVD is supported by further genetic
studies using SNPs within the LPA gene region. A study of
cases with myocardial infarction and controls investigated
several SNPs in that gene region. Besides several other
SNPs, rs10455872 and rs3798220 showed the strongest asso-
ciations with myocardial infarction [37]. rs10455872 is an
intronic SNP and rs3798220 results in an amino acid substi-
tution in the protease domain of LPA. Both SNPs were de-
scribed to be associated with small apo(a) isoforms and high
Lp(a) levels. rs10455872 was associated with a 1.47-fold and
rs3798220 with a 1.68-fold increased risk for CHD over non-
Lp(a): high high high low high high low low low low low low










Fig. 4 Simplified illustration how Mendelian segregation of small and
large apo(a) isoforms and thereby the transmission of high or low Lp(a)
concentrations and risk for CVD, respectively, works. It is randomly
determined at the time of conception which of the two alleles from the
father and which of the two alleles from the mother are transmitted to the
offspring. The height of the bars represents the size of the isoforms. The
three boxes illustrate the most common situations where both parents
carry at least one small apo(a) isoform each (left box), where at least on
parent carries one small apo(a) isoform (middle box) or where both
parents carry only large apo(a) isoforms (right box). Underneath the
typically observed Lp(a) concentrations (high or low) and the
associated risk for CVD (high or low) are given. It should be pointed
out that exceptions from the rules can occur since also other variants than
the KIV repeat polymorphism have an influence on Lp(a) concentrations
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carriers. Individuals who carried at least one risk allele of the
two SNPs had a 1.51-fold elevated risk for myocardial infarc-
tion and subjects carrying two and more risk alleles of these
two SNPs had a 2.57-fold increased risk [37]. These findings
have been confirmed by a recent meta-analysis [60] and clear-
ly underscore the LPA gene as a risk gene for CVD. This
becomes even more accented in comparison to other genes
for CAD detected by GWAS that were associated with odds
ratios between 1.06 and 1.29 [61].
The Disadvantage of Well-Known SNPs
These impressive findings were a turning point which brought
Lp(a) back to the stage of interest. Commercial laboratories
started to offer the genotyping of the two SNPs rs10455872
and rs3798220 for diagnostic purpose which is easily possible
in a high-throughput manner and with a simple interpretation.
They were claimed to tag carriers of small apo(a) isoforms.
However, the minor allele frequencies of these two SNPs are
only 7 and 2 %, respectively. It was therefore quite interesting
to see the data from almost 3000 individuals of a general
Caucasian population that was genotyped for these two
SNPs and phenotyped for the apo(a) isoforms [62]. The results
clearly showed that 47 % of all subjects expressing a small
apo(a) isoform were not tagged by one of these two high-risk
SNPs. Furthermore, about 11% of all subjects carrying at least
one minor allele of these two SNPs did actually not have a
small apo(a) isoform. That means that these two SNPs are far
from being a good surrogate for risk evaluation instead of
measurement of small apo(a) isoforms since roughly half of
the small apo(a) isoforms will remain undetected when only
these two SNPs are genotyped. As stated figuratively, from a
population perspective we might see the tip of the iceberg but
we might underestimate the size [62].
In addition, the situation might be different for various
ethnicities. For example, a study investigating rs3798220
and K-IV repeat number in several ethnicities revealed that
this variant was not found in Africans. Allele frequencies in
East and Southeast Asians ranged from 2.9 to 11.6 %, and
were very low (0.15 %) in CAD cases and controls from
India. The variant was neither associated with small KIV
CNV alleles nor elevated Lp(a) concentrations in Asians.
The study concluded that it is unlikely that this SNP confers
atherogenic potential on its own and that this SNP does not
explain Lp(a)-attributed risk for CAD in Asian Indians [63].
This might also be the reason why a recent GWAS for CAD
Japanese patients did not find the LPA locus to be associated
with CAD [64] although case–control studies consistently
found an association of the KIV repeat polymorphism with
CAD in e.g., Chinese CAD patients and controls [55, 65].
Haplotypes Instead of Single SNPs
To increase the number of SNPs by creating haplotypes in-
stead of single SNPs for risk prediction was a further idea
which was followed by a GWAS for myocardial infarction
[66]. The authors used haplotypes built from four SNPs, two
in LPA (rs7767084 and rs10755578) and two in the neighbor-
ing genes LPAL2 (rs3127599) and SLC22A3 (rs2048327)
gene. A rare haplotype with a frequency of roughly 2 % was
associated with an 82 % higher risk (OR 1.82, 95%CI 1.57-
2.12) and a more common haplotype with a frequency of
about 16 % had a 20 % higher risk (OR 1.20, 95%CI 1.13-
1.28) for myocardial infarction [66]. Once again, this only
supports the LPA gene as a risk gene for CVD but does not
improve risk prediction when compared to apo(a) isoforms
since either only for a small group of 2 % a tremendously
increased risk or for a larger group of 16% a slightly increased
risk is predicted.
qPCR to Quantify the Sum of KIV Repeats of Both
apo(a) Alleles
A further impressive genetic approach to support Lp(a) as a
risk factor for CVD came from Kamstrup and colleagues who
used qPCR to quantify the copy number of KIV type-2 repeats
in >40,000 subjects. This method sums up the number of both
apo(a) alleles and cannot distinguish each of the two alleles.
They observed in the Copenhagen City Heart Study that indi-
viduals in the lower quartile of the sum of copy number in
their genome had an adjusted hazard ratio for myocardial in-
farction of 1.50 compared to those in the highest quartile of
copy number. The KIV type-2 CNV explained roughly 25 %
of the variability in Lp(a) levels [53], which is lower than in
other studies of European populations using methods such as
apo(a) isoforms byWesternblot or separated alleles by pulsed-
field gel electrophoresis. However, these estimates in risk and
120 patients with CAD and Lp(a) >95th percentile
Stage 1: Lipid-lowering medication
until maximal tolerated doses (mean5.6 yrs)
Stage 2: Combined lipid apheresis 
+ lipid-lowering medication (mean 5.0 yrs)
Lp(a) reduced by 73%, LDL-C reduced by 65% 
Major coronary events reduced by 86% 
LDL-C in stage1 ≤100 mg/dL
true LDL-C:  -5 mg/dL 
major events-89%
Similar reductionin events
LDL-C in stage 1 >100 mg/dL
true LDL-C:  -61 mg/dL 
major events-85%
Fig. 5 Study design and summary of the results of the study by Jaeger
et al. [89] that investigated the effect of Lp(a)-lowering by lipid apheresis
in very high-risk patients. BTrue LDL-C^ is considered to be LDL-
cholesterol without the cholesterol from the Lp(a) particles. The Lp(a)-
derived cholesterol is not accessible for therapeutic interventions with
statins and is about 45 % of the Lp(a) concentration. For extended
explanation, see text. Figure taken with permission from reference [1]
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unexplained variability determined by qPCR are most likely
an underestimation due to the special characteristics of qPCR
(see below).
All these approaches and data together provide pronounced
genetic evidence that Lp(a) is an emerging genetic risk factor
for cardiovascular disease that is independent of other classi-
cal risk factors including lipids.
Advantages and Disadvantages of Various Methods
for Risk Prediction
The measurement of Lp(a) concentrations comes probably
most closely to the component which actively contributes to
risk. It measures the protein of interest and can be done in
high-throughput. Since a protein and not a genetic polymor-
phism is measured, no genetic counseling is required in most
countries. A disadvantage is the fact that the Lp(a) measure-
ment is still insufficiently standardized [50, 51, 67, 68]. This is
caused by the repetitive structure of the KIV copies and most
assays have no proof that the applied antibodies are directed
against unique non-repetitive elements of apo(a). Although
Lp(a) seems to be relatively stable throughout life [4, 69],
there are several conditions known that influence Lp(a) con-
centrations secondarily (for review see [1]).
Westernblot analysis of the number of KIV repeats is quite
laborious and only few laboratories have established the meth-
od of SDS agarose gel electrophoresis. Nevertheless, from all
methods that investigate apo(a) genetic polymorphisms, it
provides the most comprehensive information and is very
suitable for risk prediction. This has to be seen in the context
of a peculiarity of this risk factor: roughly 30–50 % of all
individuals show only one isoform in their plasma although
95 % of the population should be heterozygous and show two
isoforms. Part of this discrepancy can be explained by the
resolution of the method which does not allow separating
two isoforms that have only a difference of 1–2 KIV repeats.
However, the major part of this discrepancy is explained by
the fact that many subjects express only one apo(a) isoform as
protein although two isoforms are expressed at the DNA level
[26, 27]. Factors which influence the protein expression or
non-expression are currently insufficiently understood. The
Westernblot analysis of KIV repeats is among all polymor-
phism methods the most informative one, since it considers
only the variants that make it to the plasma level. The other
non-expressed isoform, although scientifically interesting,
might not contribute to the risk. A further advantage of this
method is that genetic counseling is not required in most of the
countries since not DNA but the protein is investigated.
Furthermore, it is more informative than Lp(a) plasma con-
centrations for risk prediction in certain patient groups where
Lp(a) concentration changes secondarily in a substantial
manner as this is the case in patients with chronic kidney
disease [1, 2, 70–73].
Pulsed field gel electrophoresis provides the number of
KIV repeats at the DNA level for each of the two apo(a)
isoforms and can be used for risk prediction although it might
be less informative than Westernblot analysis. This can be
explained by the fact, that the expression level of each protein
isoform is not investigated by this method. The method is very
laborious and takes up to 2 weeks. Most importantly, it re-
quires a special, time and costly DNA preparation since non-
fragmented DNA is required. This is no longer the case when
DNA is already extracted from full-blood with conventional
DNA extraction methods since they generate DNA fragments
of mostly 30 to 100 kb in size. Therefore, the analysis of
ancient DNA samples is not possible. The method ignores
the expression status of the protein and is partially reliable
for risk prediction. Furthermore, it requires genetic counseling
in most countries.
The qPCR (see above) provides the sum of the KIV repeats
of the two alleles and some information gets lost since the
expression status of the protein is not considered. The conse-
quence is that individuals with one very short KIV-2 repeat
allele and one very large allele end up in the same category as
individuals with two intermediate copy number alleles. These
two situations are, however, associated with very distinct
Lp(a) concentrations. On the other hand, qPCR is a high-
throughput method suitable for large epidemiological studies
but requires genetic counseling if analysis is done for single
individuals.
SNPs such as rs10455872 and rs3798220 became quite
popular recently since they are easy to analyze in the routine
lab. These two SNPs tag only half of the small apo(a) isoforms
resulting in a large frequency of false negatives and are there-
fore not as good for risk prediction. They ignore the expres-
sion status of the protein and genetic counseling might be
required.
One Grey Spot on Lp(a) - Is a Lowering of Lp(a)
Beneficial?
After the strong genetic support that Lp(a) is a risk factor and
not only a risk marker for CVD, a burning question is whether
therapeutic lowering of Lp(a) indeed also lowers the CVD
risk. Despite therapeutic options being on the horizon, it turns
out that this key question is not easy to investigate since there
are no simple means to lower Lp(a) effectively without chang-
ing other lipid risk factors at the same time. It will be difficult,
if not impossible to disentangle effects of LDL-C and Lp(a)
lowering as well as other changes in lipoproteins. Several of
the options fell away in the meanwhile since the further de-
velopment of some drugs was stopped for other reasons not
necessarily connected to Lp(a).
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Niacin was considered by many researchers as kind of
magic bullet since it increases HDL-cholesterol markedly
and as a further positive effect it lowers triglycerides, LDL-
C and also Lp(a). Recent turnover studies demonstrated that
niacin decreases production rates of apo(a) [74, 75]. However,
two clinical trials in patients with optimally low levels of
LDL-C failed to show any further clinical benefit on CVD
events when niacin was added to simvastatin [76, 77]. We
do not really know whether niacin would be beneficial in
patients with isolated Lp(a) elevations since we are missing
trials that were designed to elucidate this question.
Furthermore, niacin is no longer available in most countries
after the two studies have failed [76, 77].
Cholesteryl ester transfer protein (CETP) inhibitors are a
further drug class that was also not designed to lower Lp(a).
CETP is a major player in the reverse cholesterol transport and
inhibitors of that protein markedly increase HDL-cholesterol
concentrations. They also lower Lp(a) by 20–40 % [78]. Five
drugs have been developed and they increased HDL-
cholesterol by up to more than 100 %. However, phase-III
trials resulted in premature stops of three of the trials either
due to side-effects (torcetrapib) or futility (dalcetrapib and
evacetrapib).
Other treatment options target the apo(a) synthesis using
antisense oligonucleotide against apolipoprotein B
(mipomersen) [79, 80] or apo(a) [81], thyroid hormone ana-
logue therapies [82] or microsomal triglyceride transfer pro-
tein inhibitors [83], but clinical outcome data are still missing.
Recently, data from a randomized, double-blind, placebo-con-
trolled, phase 1 study of a second-generation antisense drug
designed to reduce the synthesis of apolipoprotein(a) in the
liver have been published. This therapy resulted in dose-de-
pendent, mean percentage decreases in plasma Lp(a) concen-
tration between 40 and 78 % [81]. If this therapy comes to
phase 3 trials, it will be one of the few possibilities that might
be able to investigate whether an isolated lowering of Lp(a)
indeed lowers CVD outcomes as well.
A major hope for lowering Lp(a) concentrations are human
monoclonal antibodies to proprotein convertase subtilisin/
kexin type 9 (PCSK9) [84]. PCSK9 is a protein synthesized
and secreted by hepatocytes that binds to the LDL-receptor to
mark it for lysosomal degradation. Inhibitors of PCSK9 not
only substantially lower LDL-C but also Lp(a) concentrations.
This finding was a major surprise since statins are also known
to have a pronounced effect on LDL-C by upregulation of the
LDL receptor but not on Lp(a) concentrations [47–49]. From
statin trials it has been concluded that Lp(a) does not bind to
the LDL receptor. However, contrary to expectations, inhibi-
tors of PCSK9 also result in a higher availability of LDL
receptors but show a significant reduction of Lp(a) in a
dose-dependent manner in subjects with hypercholesterolemia
who are already on lipid-lowering therapy [85]. The reduction
in Lp(a) is proportional to the baseline Lp(a) [86]. The precise
mechanism via which anti-PCSK9 lowers Lp(a) remains to be
elucidated. It could well be that PCSK9 also regulates a re-
ceptor other than the LDL receptor that is responsible for the
uptake of Lp(a). Although the main outcome trials are still
under way, recent post-hoc and pre-specified exploratory data
analyses of outcome studies revealed that the use of PCSK9
inhibitors in addition to standard therapy and/or statin therapy
at the maximum tolerated dose significantly reduced LDL-C
levels and reduced the incidence of cardiovascular events [87,
88]. It has to be seen whether trials in patients with isolated
Lp(a) elevations will be performed in the future and whether
they will show an effect on CVD outcomes.
The best evidence for a beneficial effect of Lp(a)-lowering
that we currently have, comes from apheresis studies. Again,
these studies are at first glance not perfect since this procedure
removes Lp(a) and LDL-C simultaneously. However, a study
by Jaeger and colleagues [89] used a sophisticated
design (Fig. 5) and selected patients with Lp(a) levels above
the 95th percentile who continued to experience a high rate of
major adverse coronary events (MACE) despite receiving the
maximum tolerated doses of lipid-lowering drug treatment
and successful lowering of LDL-C in the first and retrospec-
tive phase of the study that lasted on average 5.6 years. In the
second and prospective phase, patients underwent LDL aphe-
resis besides the lipid-lowering drug treatment for on average
5 years. In this phase Lp(a) was lowered on average by 73 %
and the rate of MACE decreased dramatically by 86 % com-
pared to the first study phase. To exclude that this decrease in
MACE was only due to further lowering of LDL-C levels, the
authors analyzed a subgroup of patients who had already
LDL-C ≤100 mg/dL before the start of the apheresis phase.
This Bmeasured LDL-C^ in their plasma was mainly choles-
terol due to their very high Lp(a) concentrations and the Btrue
LDL-C^ was on average only 23 mg/dL. Consequently, aphe-
resis selectively and dramatically lowered Lp(a) in these pa-
tients and the true LDL-C dropped only from 23 to 18 mg/dL.
Most importantly, the effect onMACE in this subgroupwas of
the same magnitude as in the subgroup that started with mea-
sured LDL-C concentrations above 100 mg/dL (−89 vs. -
85 %, respectively). Therefore, the very small reduction in
the true LDL-C in the low LDL-C group by 5 mg/dL is too
small to explain this dramatic reduction in MACE by 89 %
[89]. In a further study in patients with isolated elevation of
Lp(a), progressive cardiovascular disease, and maximally tol-
erated lipid-lowering medication, lipid apheresis effectively
lowered the incidence rate of cardiovascular events [90].
Further promising evidence that an isolated lowering of
Lp(a) is beneficial comes from a small study in patients with
CHD, Lp(a) >50mg/dL, and LDL-C below 100mg/dL and on
chronic statin therapy. Half of the patients underwent a spe-
cific Lp(a) apheresis on a weekly basis. Both patient groups
received a quantitative coronary angiography analysis of per-
cent diameter stenosis before and 18 months after start of
Cardiovasc Drugs Ther (2016) 30:87–100 95
therapy. Lp(a) decreased on average by 73 % without signif-
icant changes in true LDL-C. The mean percent diameter ste-
nosis at 18 months as primary efficacy end-point decreased by
5 % in the Lp(a) intervention group and increased by 5 % in
the control group that received only statins [91].
Three Major Surprises Concerning Lp(a)
During Recent Years
Lp(a) and Aortic Valve Calcification, Aortic Valve
Stenosis and Heart Failure
A recent GWAS identified rs10455872 of the LPA gene
to be significantly associated with the presence of
aortic-valve calcification with an odds ratio per allele
of 2.05 (95%CI 1.63–2.57). In prospective analyses,
the LPA genotype was associated with incident aortic
stenosis and aortic-valve replacement [92]. In large stud-
ies from the general population, elevated Lp(a) levels
and corresponding LPA risk genotypes predicted in-
creased risk of incident aortic valve stenosis and the
risk estimates were very similar to the observations for
myocardial infarction [93, 94]. Furthermore, Lp(a) levels
were also associated with aortic valve calcification in
asymptomatic patients with familial hypercholesterol-
emia who were free of symptomatic CVD or symptoms
suggestive of ischemic heart disease at the time of re-
cruitment [95]. A prospective study in 220 patients with
mild to moderate aortic stenosis described that progres-
sion of aortic stenosis was faster in the top tertiles of
Lp(a) concentrations as well as oxidized phospholipids
[96].
Lp(a) transports oxidized phospholipids with a high con-
tent in lysophosphatidylcholine. It has recently been demon-
strated that autotaxin transforms lysophosphatidylcholine into
lysophosphatidic acid that promotes deposition of hydroxyap-
atite of calcium in aortic valve. Autotaxin is transported in the
aortic valve by Lp(a) and is also secreted by valve interstitial
cells. This promotes inflammation and mineralization of the
aortic valve [97].
The most recent findings published were on an association
between Lp(a) concentrations and heart failure in more than
98000 individuals from the general population of Denmark
[98]. In 4122 of them heart failure had been diagnosed during
the observation period. Lp(a) concentrations in the upper
tertile were significantly associated with heart failure com-
pared to the lowest tertile and this association was graded
within the upper tertile: HR=1.24 (95%CI: 1.08-1.42) for
the 67th to 90th percentiles, HR=1.57 (95%CI: 1.32-1.87)
for the 91st to 99th percentiles, and HR=1.79 (95%CI: 1.18
to 2.73) for levels >99th percentile compared to the lowest
tertile corresponding to a population-attributable risk of 9 %.
LPA risk genotypes that are associated with high Lp(a) con-
centrations were in line with this association. When partici-
pants with a myocardial infarction or aortic valve stenosis
were excluded, the risk estimates were attenuated and media-
tion analysis revealed that 63 % of heart failure risk was me-
diated via myocardial infarction or aortic valve stenosis [98].
Lp(a) and Venous Thromboembolism
The high homology of apo(a) and plasminogen sug-
gested a link to the fibrinolytic system with blood
clotting and fibrinolysis. It was therefore not clear
whether the culprit is the development of atherosclerosis
or thrombosis. Again a Mendelian randomization study
in more than 41000 individuals has shed some light into
the dark. Neither Lp(a) tertiles nor the sum of K-IV
repeats were associated with the risk of venous throm-
bosis in general population studies [99]. A further study
including 4607 cases with venous thromboembolism in-
vestigated the two LPA variants rs10455872 and
rs3798220 and did also not find an association [100].
However, both studies found associations with CVD
[99, 100].
However, a meta-analysis of eight studies including
589 children with venous thromboembolism and 1441
controls described elevated Lp(a) levels to be associated
with an odds ratio of 4.50 (3.19–6.35) for first onset
venous thromboembolism. The association with 135 re-
current cases of venous thromboembolisms was not sta-
tistically significant [101].
Lp(a) and Diabetes Mellitus
When Mora et al. described an association between very
low Lp(a) concentrations and type 2 diabetes mellitus
(T2DM) a few years ago, it was a major surprise
[102]. The highest risk was found for Lp(a) <1 mg/dL
(lowest 2.6 % of observations) with an odds ratio of
1.57 when compared to higher values. When the risk
group was changed to Lp(a) concentrations below
4 mg/dL (equals the lowest quintile), the size of the
risk was markedly attenuated to 1.18 [102]. These find-
ings were contrary to expectations and the study could
not clarify the causality between low Lp(a) levels and
T2DM and could not exclude Breverse causation^.
Kamstrup and Nordestgaard could not only replicate
the association between low Lp(a) concentrations and
T2DM in a large Danish study but also demonstrated
that the highest quintile of the sum of the KIV-2 repeats
from the two apo(a) alleles is associated with T2DM
[103]. This quintile combines large isoforms and is as-
sociated with low and medium Lp(a) concentrations and
therefore supports causality and excludes that the
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association between low Lp(a) concentrations and
T2DM is merely due to reverse causation or confound-
ing. Two other studies followed and confirmed the as-
sociation between low Lp(a) concentrations and T2DM
[104, 105]. An investigation in more than 10000
Chinese individuals extended the findings and found
an association not only between low Lp(a) concentra-
tions and prevalence of T2DM but also prevalent predi-
abetes, insulin resistance and hyperinsulinemia [105].
Mendelian randomization studies that investigated an
association between the SNP rs10455872 and T2DM
caused more confusion than support for causality [103,
104]. The carrier-status of this SNP is already well
known for its association with CVD since it is associ-
ated with high Lp(a) concentrations [37]. The authors of
these two studies [103, 104] used the non-carrier status
of rs10455872 as a surrogate for genetically determined
low Lp(a) concentrations to investigate the causality for
the association between low Lp(a) concentrations and
T2DM. Since they did not find an association between
the non-carrier status of rs10455872 and T2DM, a caus-
al role of Lp(a) concentrations has been called into
question [103, 104]. As we discussed recently [106],
the non-carrier status of rs10455872 includes already
86 % of the population with a very wide range in
Lp(a) concentrations and with the inclusion of large
and small apo(a) isoforms [103]. We have to bear in
mind that the association of Lp(a) and T2DM is espe-
cially seen in subjects with ultra-low Lp(a) concentra-
tions (e.g., <1 mg/dL) and was already weaker, when
the low class was extended to the lowest quintile [103].
With other words, the non-carrier status of the SNP
explains the wrong range of the Lp(a) values which
might Bdilute^ the association of very low Lp(a) levels
with T2DM. Therefore, rs10455872 is obviously an im-
precise instrument to support or exclude causality of
low Lp(a) levels for T2DM [106].
One might ask the question whether it would be counter-
productive to lower Lp(a) to avoid CVD events but simulta-
neously increase the risk for T2DM? This is probably not the
case since the risk for T2DM is especially elevated for persons
with very low Lp(a) concentrations and an Lp(a)-lowering
therapy will not bring Lp(a) in these concentration ranges.
Conclusions
Lp(a) plays a major role for complex diseases such as
cardiovascular disease and type-2 diabetes mellitus.
Genetic studies helped to elucidate the causal role of
this lipoprotein for these diseases. Especially this
knowledge makes it reasonable to search for therapeutic
options to lower Lp(a) concentrations to decrease the
risk for cardiovascular disease.
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